Retrieve available abstracts of 13 articles: HTML format
Single Articles
March 2025
SUN X, Zhang C, Fan B, Liu Q, et al Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both
imatinib-sensitive and imatinib-resistant CML cells.
Biochem Pharmacol. 2025;233:116763. PubMedAbstract available
January 2025
HAN YU P, Yan Zhang Z, Yuan Kang Y, Huang P, et al Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis,
potential therapeutics and future directions.
Biochem Pharmacol. 2025;233:116774. PubMedAbstract available
November 2024
LIU W, Dou C, Zhang C, Chen P, et al PX-478 induces apoptosis in acute myeloid leukemia under hypoxia by inhibiting
the PI3K/AKT/mTOR pathway through downregulation of GBE1.
Biochem Pharmacol. 2024 Nov 9:116620. doi: 10.1016/j.bcp.2024.116620. PubMedAbstract available
October 2024
ZHAO J, Wu S, Wang D, Edwards H, et al Panobinostat sensitizes AraC-resistant AML cells to the combination of
azacitidine and venetoclax.
Biochem Pharmacol. 2024;228:116065. PubMedAbstract available
XIE N, Zhong L, Liu L, Fang Y, et al Corrigendum to "Autophagy contributes to dasatinib-induced myeloid
differentiation of human acute myeloid leukemia cells" [Biochem. Pharmacol. 89/1
(2014) 74-85].
Biochem Pharmacol. 2024;230. PubMed
June 2024
CHIOU JT, Lee YC, Huang CH, Wang LJ, et al Corrigendum to "Inhibition of Sp1-mediated survivin and MCL1 expression
cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to
human leukemia cells" [Biochem. Pharmacol.188 (2021) 114544].
Biochem Pharmacol. 2024;226:116359. PubMed
May 2024
SUN L, Rao S, Kerim K, Lu J, et al A chemically adjustable BMP6-IL6 axis in mesenchymal stem cells drives acute
myeloid leukemia cell differentiation.
Biochem Pharmacol. 2024;225:116262. PubMedAbstract available
April 2024
CHIOU JT, Chang LS ONC212 enhances YM155 cytotoxicity by triggering SLC35F2 expression and
NOXA-dependent MCL1 degradation in acute myeloid leukemia cells.
Biochem Pharmacol. 2024;224:116242. PubMedAbstract available
March 2024
DI GIORGIO C, Morretta E, Lupia A, Bellini R, et al Bile acids serve as endogenous antagonists of the Leukemia inhibitory factor
(LIF) receptor in oncogenesis.
Biochem Pharmacol. 2024;223:116134. PubMedAbstract available
February 2024
HURRISH KH, Su Y, Patel S, Ramage CL, et al Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through
suppression of OXPHOS and/or purine biosynthesis in vitro.
Biochem Pharmacol. 2024;220:115981. PubMedAbstract available
November 2023
CHIOU JT, Lee YC, Chang LS Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to
chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition.
Biochem Pharmacol. 2023 Nov 19:115934. doi: 10.1016/j.bcp.2023.115934. PubMedAbstract available
October 2023
HAN H, Zhao C, Liu M, Zhu H, et al Mitochondrial complex I inhibition by homoharringtonine: A novel strategy for
suppression of chronic myeloid leukemia.
Biochem Pharmacol. 2023 Oct 21:115875. doi: 10.1016/j.bcp.2023.115875. PubMedAbstract available
September 2023
OIKONOMOU A, Valsecchi L, Quadri M, Watrin T, et al High-throughput screening as a drug repurposing strategy for poor outcome
subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.
Biochem Pharmacol. 2023 Sep 15:115809. doi: 10.1016/j.bcp.2023.115809. PubMedAbstract available